June 15, 2025 10:18 PM EDTUpdated 06:09 AM

Sarepta halts Duchenne gene therapy in some patients after second death

Lei Lei Wu

News Reporter

Sarepta Therapeutics reported a second patient death due to liver failure related to its Duchenne muscular dystrophy gene therapy Elevidys, and said it’s suspending shipments …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sarepta halts Duchenne gene therapy in some patients after second death

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Another round of consolidation is coming, FDA commissioner tells staff

KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

FDA's oncology adcomm to review GSK's Blenrep relaunch plans

McKesson leads the charge in revolutionizing precision oncology in community practices

Sarep­ta halts Duchenne gene ther­a­py in some pa­tients af­ter sec­ond death

Lei Lei Wu

News Reporter

Sign up to read this article for free.

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front

FDA's on­col­o­gy ad­comm to re­view GSK's Blenrep re­launch plans

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

Sarepta halts Duchenne gene therapy in some patients after second death

Another round of consolidation is coming, FDA commissioner tells staff

KalVista says FDA delayed decision on HAE drug, citing ‘heavy workload’

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

FDA's oncology adcomm to review GSK's Blenrep relaunch plans

McKesson leads the charge in revolutionizing precision oncology in community practices